Lower risks of cirrhosis and hepatocellular carcinoma with GLP-1RAs in type 2 diabetes: A nationwide cohort study using target trial emulation framework.
Chun-Ting YangWen-Yu YaoChen-Yi YangZi-Yang PengHuang-Tz OuShihchen KuoPublished in: Journal of internal medicine (2023)
Among T2D patients who require injectable GLAs, the use of GLP-1RAs versus LAIs was associated with lower risks of cirrhosis and HCC.